Publications en collaboration avec des chercheurs de Centro de Investigación Biomédica en Red sobre Enfermedades Hepáticas y Digestivas (8)

2024

  1. The ‘BCLC upon progression’ classification: After repeated validation, it is time to incorporate it in trial design

    Liver International

2023

  1. Metabolic dysfunction–associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment

    Journal of Physiology and Biochemistry, Vol. 79, Núm. 4, pp. 869-879

2022

  1. Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study

    Journal for immunotherapy of cancer, Vol. 10, Núm. 11

2021

  1. Inmunoterapia en hepatocarcinoma

    Revisiones en Cancer, Vol. 35, Núm. 5, pp. 300-312

  2. Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice

    European Journal of Radiology, Vol. 135

2020

  1. The Pattern of Progression Defines Post-progression Survival in Patients with Hepatocellular Carcinoma Treated with SIRT

    CardioVascular and Interventional Radiology, Vol. 43, Núm. 8, pp. 1165-1172

2017

  1. Neutrophil-to-lymphocyte ratio predicts survival in European patients with hepatocellular carcinoma administered sorafenib

    Oncotarget, Vol. 8, Núm. 61, pp. 103077-103086

2016

  1. A comparison of survival in patients with hepatocellular carcinoma and portal vein invasion treated by radioembolization or sorafenib

    Liver International, Vol. 36, Núm. 8, pp. 1206-1212